Uses of dopamine, deuterated dopamine, a deuterated dopamine derivative such as deuterated L-dopa, or a pharmaceutically acceptable salt thereof, in inhibiting the development or progression of visual disorders, such as myopia, or a visual disorder associated with diabetic retinopathy or Parkinson's disease, are provided.

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient,

##STR00001##

wherein m and n are each independently an integer of 0 to 5; m+n≧1; and each aromatic ring of the compound represented by Formula (I) may be substituted.

New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

The invention provides an isolated limbal stem or progenitor cell (LSC) population or LSC-like population comprising a chemically synthesized, recombinant or isolated nucleic acid encoding PAX6 integrated into a chromosome, or alternatively, not integrated remaining as an extrachromosomal genetic material, wherein the isolated LSC population is substantially free of non-LSC cells or wherein the LSC-like population is substantially free of non-LSC-like cells, or wherein the isolated LSC or LSC-like population is substantially free of non-LSC and non-LSC-like cells and uses thereof.

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.

The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.